QRG Capital Management Inc. Has $1.37 Million Position in Becton, Dickinson and Company $BDX

QRG Capital Management Inc. increased its holdings in Becton, Dickinson and Company (NYSE:BDX) by 64.6% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,733 shares of the medical instruments supplier’s stock after purchasing an additional 3,429 shares during the period. QRG Capital Management Inc.’s holdings in Becton, Dickinson and Company were worth $1,373,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in BDX. Auto Owners Insurance Co lifted its position in shares of Becton, Dickinson and Company by 22,225.2% during the 4th quarter. Auto Owners Insurance Co now owns 40,711,035 shares of the medical instruments supplier’s stock worth $790,079,000 after buying an additional 40,528,680 shares during the period. Wellington Management Group LLP raised its stake in Becton, Dickinson and Company by 9,056.3% during the third quarter. Wellington Management Group LLP now owns 5,232,086 shares of the medical instruments supplier’s stock worth $979,290,000 after acquiring an additional 5,174,944 shares in the last quarter. Vanguard Group Inc. raised its stake in Becton, Dickinson and Company by 13.0% during the fourth quarter. Vanguard Group Inc. now owns 36,678,939 shares of the medical instruments supplier’s stock worth $7,118,282,000 after acquiring an additional 4,223,149 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Becton, Dickinson and Company by 23,219.2% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 4,155,709 shares of the medical instruments supplier’s stock valued at $769,397,000 after acquiring an additional 4,137,888 shares during the period. Finally, Norges Bank acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $734,321,000. 86.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, CEO Thomas E. Polen, Jr. sold 2,764 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $146.35, for a total value of $404,511.40. Following the transaction, the chief executive officer owned 110,163 shares in the company, valued at $16,122,355.05. This trade represents a 2.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $145.66, for a total value of $160,226.00. Following the completion of the sale, the executive vice president owned 13,172 shares of the company’s stock, valued at approximately $1,918,633.52. The trade was a 7.71% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 5,188 shares of company stock valued at $765,120 over the last three months. Insiders own 0.40% of the company’s stock.

Becton, Dickinson and Company Trading Up 0.5%

BDX opened at $156.36 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $43.08 billion, a PE ratio of 39.58, a PEG ratio of 11.01 and a beta of 0.21. Becton, Dickinson and Company has a 1-year low of $127.59 and a 1-year high of $187.35. The firm has a 50-day moving average price of $148.08 and a two-hundred day moving average price of $168.55.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same period in the prior year, the business earned $3.35 earnings per share. Becton, Dickinson and Company’s quarterly revenue was up 5.2% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. As a group, equities analysts anticipate that Becton, Dickinson and Company will post 12.62 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th were given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date was Tuesday, June 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 106.33%.

Analyst Ratings Changes

Several brokerages recently issued reports on BDX. Weiss Ratings downgraded shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. The Goldman Sachs Group dropped their price objective on shares of Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating for the company in a report on Wednesday, May 27th. Barclays lifted their target price on shares of Becton, Dickinson and Company from $202.00 to $204.00 and gave the company an “overweight” rating in a research note on Monday, May 11th. Wells Fargo & Company boosted their target price on Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an “equal weight” rating in a report on Friday, May 8th. Finally, Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research report on Tuesday, April 14th. Seven analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $180.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.